ArticleNature medicine2018
Antigen discovery and specification of immunodominance hierarchies for MHCII-restricted epitopes.
Article in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed.
- Article
- Discovery of CD4+ T cell-recognized B. pertussis antigens that reduce airway colonization.JCI insight · 2026Article
- Immunopeptidomics reveals conserved and abundant Francisella tularensis proteins as immunogenic CD4 T cell antigens in mice.PLoS pathogens · 2026Article
- Artificial intelligence in peptide cancer vaccine design: from neoantigen discovery to immunogenicity prediction.Frontiers in genetics · 2026Review
- Advances in nanocarrier-mediated cancer therapy: Progress in immunotherapy, chemotherapy, and radiotherapy.Chinese medical journal · 2025Review
- Harnessing immunopeptidomics for next-generation vaccines against intracellular bacterial pathogens.Molecular biology reports · 2025Review
- Antigen-presenting innate lymphoid cells induced by BCG vaccination promote a respiratory antiviral immune response through the skin‒lung axis.Cellular & molecular immunology · 2025Article
- High-throughput discovery of MHC class I- and II-restricted T cell epitopes using synthetic cellular circuits.Nature biotechnology · 2025Article
- Cancer Vaccines and Beyond: The Transformative Role of Nanotechnology in Immunotherapy.Pharmaceutics · 2025Review
- Designing multifunctional recombinant vaccines: an engineering strategy based on innovative epitope prediction-guided splicing.Theranostics · 2025Article
- Recent Advances in Host Immune Mechanisms AgainstJournal of inflammation research · 2025Review
- Neoantigens: new hope for cancer therapy.Frontiers in oncology · 2025Review
- Review
- Review
- The genetic relationships between immune cell traits, circulating inflammatory proteins and preeclampsia/eclampsia.Frontiers in immunology · 2024Article
- A Cardiolipin fromJournal of the American Chemical Society · 2023Article
- Investigating the human and nonobese diabetic mouse MHC class II immunopeptidome using protein language modeling.Bioinformatics (Oxford, England) · 2023Article
- HLA-II immunopeptidome profiling and deep learning reveal features of antigenicity to inform antigen discovery.Immunity · 2023Article
- M cell maturation and cDC activation determine the onset of adaptive immune priming in the neonatal Peyer's patch.Immunity · 2023Article
- Untangling the CD4 T cell response to the microbiota.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Identifying immunodominant T cell epitopes remains a significant challenge in the context of infectious disease, autoimmunity, and immuno-oncology. To address the challenge of antigen discovery, we developed a quantitative proteomic approach that enabled unbiased identification of major histocompatibility complex class II (MHCII)-associated peptide epitopes and biochemical features of antigenicity. On the basis of these data, we trained a deep neural network model for genome-scale predictions of immunodominant MHCII-restricted epitopes. We named this model bacteria originated T cell antigen (BOTA) predictor. In validation studies, BOTA accurately predicted novel CD4 T cell epitopes derived from the model pathogen Listeria monocytogenes and the commensal microorganism Muribaculum intestinale. To conclusively define immunodominant T cell epitopes predicted by BOTA, we developed a high-throughput approach to screen DNA-encoded peptide-MHCII libraries for functional recognition by T cell receptors identified from single-cell RNA sequencing. Collectively, these studies provide a framework for defining the immunodominance landscape across a broad range of immune pathologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.